Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 711 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Fine Needle Aspiration Biopsy: How to Prepare and What to Expect October 7, 2021 Celebrating 75 years of NHS cancer care July 5, 2023 How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist February 23, 2021 Adding Sintilimab to Chemoradiotherapy Improves Event-Free Survival in Patients with High-Risk... June 24, 2024 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients... Ifosfamide May Be Treatment of Choice for Some People with Ewing... ESMO Congress 2021, 16-21 September
